Comprehensive study of neoadjuvant targeted therapy for resectable non-small cell lung cancer

BACKGROUND: Approximately 30–70% percent of patients with non-small cell lung cancer (NSCLC) still relapse after receiving complete resection and even suffer distant metastasis. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have gradually replaced chemotherapy to become the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bao, Yi, Gu, Chang, Xie, Huikang, Zhao, Shengnan, Xie, Dong, Chen, Chang, Jiang, Gening, Dai, Chenyang, Zhu, Yuming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039639/
https://www.ncbi.nlm.nih.gov/pubmed/33850890
http://dx.doi.org/10.21037/atm-21-1134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039639/
https://www.ncbi.nlm.nih.gov/pubmed/33850890
http://dx.doi.org/10.21037/atm-21-1134

Ejemplares similares